ClinicalTrials.govpublic full text
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
non-small cell lung cancer, advanced non-small cell squamous lung cancer, metastatic lung non-small cell carcinoma, metastatic lung cancer, nsclc, advanced lung carcinoma, epidermal growth factor receptor c797s, epidermal growth factor receptor g719x, egf-r positive non-small cell lung cancer, egfr-tki resistant mutation, egfr alterations, egfr l858r
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 892861
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.